Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

According to Zacks, “Teva is facing significant challenges in the form of generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Also, Teva’s shares have underperformed the generic industry in the past one year. Mylan’s earlier-than-expected launch of the first generic version of the 40-mg strength of Copaxone was a major setback for Teva. Though Teva has divested some non-core assets to cut its significant debt load and aims to cut its global workforce by more than 25% over the next two years, a clear path to growth is not visible. Estimates have gone up ahead of the company’s Q4 earnings release due to expected cost savings from the restructuring plan. Teva has a negative record of earnings surprises. “

TEVA has been the topic of a number of other research reports. Goldman Sachs Group upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Friday, December 15th. Credit Suisse Group restated an “underperform” rating and set a $8.00 target price (down previously from $14.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, November 6th. Cantor Fitzgerald set a $18.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Thursday, December 28th. Royal Bank of Canada decreased their target price on shares of Teva Pharmaceutical Industries from $21.00 to $15.00 and set an “underperform” rating on the stock in a research report on Monday, September 18th. Finally, Wells Fargo & Co restated a “market perform” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, October 5th. Eight research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries currently has a consensus rating of “Hold” and a consensus target price of $21.17.

Shares of Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.77 during midday trading on Friday, reaching $22.51. 9,905,948 shares of the company were exchanged, compared to its average volume of 25,730,000. Teva Pharmaceutical Industries has a 1 year low of $10.85 and a 1 year high of $37.94. The firm has a market capitalization of $22,150.00, a price-to-earnings ratio of -3.83, a P/E/G ratio of 1.36 and a beta of 0.54. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96.

A number of large investors have recently bought and sold shares of TEVA. Capital Research Global Investors raised its stake in Teva Pharmaceutical Industries by 13.8% during the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after purchasing an additional 9,260,426 shares during the period. FMR LLC raised its stake in Teva Pharmaceutical Industries by 16.7% during the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after purchasing an additional 6,115,853 shares during the period. Macquarie Group Ltd. raised its stake in Teva Pharmaceutical Industries by 350.3% during the third quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock worth $77,587,000 after purchasing an additional 3,429,448 shares during the period. Capital World Investors raised its stake in Teva Pharmaceutical Industries by 41.9% during the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock worth $367,686,000 after purchasing an additional 3,268,200 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. raised its stake in Teva Pharmaceutical Industries by 62.5% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 5,775,753 shares of the company’s stock worth $191,861,000 after purchasing an additional 2,221,695 shares during the period. 51.98% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries (TEVA) Downgraded by Zacks Investment Research to “Sell”” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/teva-pharmaceutical-industries-teva-downgraded-by-zacks-investment-research-to-sell/1804354.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.